Analysts Offer Predictions for ProPhase Labs, Inc.'s Q1 2025 Earnings (NASDAQ:PRPH)

ProPhase Labs, Inc. (NASDAQ:PRPH - Free Report) - Analysts at Diamond Equity issued their Q1 2025 EPS estimates for ProPhase Labs in a research report issued to clients and investors on Monday, April 22nd. Diamond Equity analyst H. Diamond forecasts that the company will post earnings per share of $0.10 for the quarter. The consensus estimate for ProPhase Labs' current full-year earnings is ($0.88) per share. Diamond Equity also issued estimates for ProPhase Labs' Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.12 EPS and Q4 2025 earnings at $0.14 EPS.

ProPhase Labs (NASDAQ:PRPH - Get Free Report) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.51) earnings per share (EPS) for the quarter. ProPhase Labs had a negative net margin of 37.81% and a negative return on equity of 29.83%. The business had revenue of $3.50 million during the quarter, compared to the consensus estimate of $10.71 million.

Separately, HC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of ProPhase Labs in a report on Wednesday, February 21st.

ProPhase Labs Trading Down 1.9 %

PRPH stock traded down $0.10 during midday trading on Wednesday, reaching $5.06. The company's stock had a trading volume of 15,554 shares, compared to its average volume of 46,003. The business's 50-day simple moving average is $5.54 and its 200-day simple moving average is $5.00. The company has a quick ratio of 2.10, a current ratio of 2.28 and a debt-to-equity ratio of 0.29. The stock has a market cap of $91.33 million, a PE ratio of -5.16 and a beta of -0.29. ProPhase Labs has a 52 week low of $4.05 and a 52 week high of $9.94.

Institutional Investors Weigh In On ProPhase Labs

Several hedge funds have recently bought and sold shares of PRPH. Tower Research Capital LLC TRC raised its holdings in shares of ProPhase Labs by 50.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,010 shares of the company's stock worth $68,000 after acquiring an additional 5,026 shares during the period. SVB Wealth LLC acquired a new stake in shares of ProPhase Labs during the third quarter worth $208,000. Finally, HighTower Advisors LLC acquired a new stake in shares of ProPhase Labs during the third quarter worth $756,000. 9.45% of the stock is currently owned by institutional investors and hedge funds.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.